Search

Search Results for "Phase 3"

Late-Breaking Phase 3 Data From AAO Retina Subspecialty Day

The Art of Drug Choice: Phase 3 Trials in Wet AMD

The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to Watch

Late-Breaking Phase 3 Data From AAO Retina Subspecialty Day

Glenn Jaffe, MD; and Rahul Khurana, MD

ARVO 2021 Coverage: TENAYA/LUCERNE Results—and Is Fluid OK in Wet AMD?

Continuous Dosing in LADDER

ASRS 2021: ARCHWAY and TENAYA/LUCERNE

New Retina Radio Journal Club: Exudative AMD in FILLY and GATHER1 Results

Faricimab in Phase 2 and 3

AAO 2021 Late Breakers: DAVIO and NORSE-2

AAO 2021: PALADIN for DME and ROP Updates From the ICROP

Thumbnail for nonifo

Phase 3 Study of Macugen in DME

Thumbnail for lwret

Phase 3 CEDAR and SEQUOIA Clinical Trial Results

Rahul N. Khurana, MD

Thumbnail for nykos

Highlights From the Phase 3 Chroma and Spectri Trials

Carl D. Regillo, MD, FACS

Thumbnail for frleh

Key Points From the Phase 3 PANORAMA Study

Charles C. Wykoff, MD, PhD, FACS

Thumbnail for bdwod

EyeGate Completes Enrollment for Phase 3 Trial of Uveitis Drug Candidate

Thumbnail for enove

Key Outcomes of SAKURA 1: A Phase 3 Study of Intravitreal Sirolimus for Noninfectious Posterior Segment Uveitis

Nikolas J.S. London, MD, Quan Dong Nguyen, MD

Thumbnail for klvel

Key Results From the Bimatoprost SR Phase 3 Study

Randy Craven, MD

Phase 3 Trial Results Examining the Efficacy of AR-15512 thumbnail

Phase 3 Trial Results Examining the Efficacy of AR-15512

Phase 3 Clinical Trial Data for EYLEA HD® (aflibercept) Injection 8 mg for the Treatment of Wet
AMD thumbnail

Phase 3 Clinical Trial Data for EYLEA HD^® (aflibercept) Injection 8 mg for the Treatment of Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

View More